Eosinophil leukocyte degranulation in response to serum-opsonized beads: C5a and platelet-activating factor enhance ECP release, with roles for protein kinases A and C

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 53, Issue 11, 1998, Pages 1066-1073

  Egesten, A ^a,b   Malm, J ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

C5a; Eosinophils; Platelet activating factor; Protein kinase A; Protein kinase C

Indexed keywords

CALPHOSTIN C; COMPLEMENT COMPONENT C5A; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; EOSINOPHIL CATIONIC PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PERTUSSIS TOXIN; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; STAUROSPORINE; THROMBOCYTE ACTIVATING FACTOR;

ARTICLE; DEGRANULATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN SECRETION;

EID: 0031736641     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.1998.tb03816.x     Document Type: Article

References (35)

1. Weller PF. The immunobiology of eosinophils. N Engl J Med 1992;324:1110-18.
2. Olsson I, Venge P. Cationic proteins of human granulocytes. II. Separation of the cationic proteins of the granules of leukemic myeloid cells. Blood 1974;44:235-46.
3. Winqvist I, Olofsson T, Olsson I. Mechanisms for eosinophil degranulation; release of the eosinophil cationic protein. Immunology 1984;51:1-8.
4. Egesten A, Gullberg U, Olsson I, Richter J. Phorbol ester-induced degranulation in adherent human eosinophil granulocytes is dependent on CD11/CD18 leukocyte integrins. J Leukoc Biol 1993;53:287-93.
5. Ross GD, Medof ME. Membrane complement receptors specific for bound fragments of C3. Adv Immunol 1985;37:217-67.
6. Egesten A, Blom M, Calafat J, Janssen H, Knol EF. Eosinophil granulocyte interaction with serum-opsonized particles: binding and degranulation are enhanced by tumor necrosis factor alpha. Int Arch Allergy Immunol 1998;115:121-8.
7. Tai P-C, Spry CJ. The effects of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 3 on the secretory capacity of human blood eosinophils. Clin Exp Immunol 1990;80:426-34.
8. Lopez AF, Williamson DJ, Gamble JR, et al. Recombinant human granulocyte-macrophage colony stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 1986;78:1220-8.
9. Lopez AF, To LB, Yang Y-C, et al. Stimulation of proliferation, differentiation, and function of human cells by primate interleukin 3. Proc Natl Acad Sci U S A 1987;84:2761-5.
10. Yamaguchi Y, Hayashi Y, Sugama Y, et al. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J Exp Med 1988;167:1737-42.
11. Slunggaard A, Vercellotti GM, Walker G, Nelson RD, Jacobs HS. Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium. J Exp Med 1990;171:2025-41.
12. Fujikawa T, Abu-Ghazaleh R, Kita H, Sanderson CJ, Gleich GJ. Regulatory effects of cytokines on eosinophil degranulation. J Immunol 1990;144:642-6.
13. Carlson M, Peterson C, Venge P. The influence of IL-3, IL-5, and GM-CSF on normal human eosinophil and neutrophil degranulation. Allergy 1993;48:437-42.
14. Koenderman L, Kuijpers TW, Blom M, Tool AT, Roos D, Verhoeven AJ. Characteristics of CR3-mediated aggregation in human eosinophils: effect of priming by platelet-activating factor. J Allergy Clin Immunol 1991;87:947-54.
15. Thorne KJI, Richardson BA, Mazza G, Butterworth AE. A new method for measuring eosinophil activating factors, based on the increased expression of CR3 alpha chain (CD11b) on the surface of activated eosinophils. J Immunol Methods 1990;133:47-54.
16. Kroegel C, Yukawa T, Dent G, Venge P, Chung KF, Barnes PJ. Stimulation of degranulation from human eosinophils by platelet-activating factor. J Immunol 1989;142:3518-26.
17. Lee TC, Lenihan DJ, Malone B, Roddy LL, Wasserman SI. Increased biosynthesis of platelet-activating factor in activated human eosinophils. J Biol Chem 1984;259:5526-30.
18. Wardlaw AJ, Moqbel R, Cromwell O, Kay AB. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest 1986;78:1701-6.
19. Tool ATJ, Koenderman L, Kok PTM, Blom M, Roos D, Verhoeven AJ. Release of platelet-activating factor is important for the respiratory burst induced in human eosinophils by opsonized particles. Blood 1992;79:2729-32.
20. Blom M, Tool AT, Roos D, Verhoeven AJ. Priming of human eosinophils by platelet-activating factor enhances the number of cells able to bind and respond to opsonized particles. J Immunol 1992;149:3672-7.
21. Gerard NP, Hodges MK, Drazen JM, Weller PF, Gerard C. Characterization of a receptor for C5a anaphylatoxin on human eosinophils. J Biol Chem 1989;264:1760-6.
22. Kernen P, Wymann MP, von Tscharner V, et al. Shape changes, exocytosis, and cytosolic free calcium changes in stimulated human eosinophils. J Clin Invest 1991;87:2012-17.
23. Klebanoff SJ, Durack DT, Rosen H, Clark RA. Functional studies on human peritoneal eosinophils. Infect Immun 1977;17:167-73.
24. Kita H, Abu-Ghazaleh RI, Gleich GJ, Abraham RT. Regulation of Ig-induced eosinophil degranulation by adenosine 3′,5′-cyclic monophosphate. J Immunol 1991; 146:2712-18.
25. Kita H, Abu-Ghazaleh RI, Gleich GJ, Abraham RT. Role of pertussis-toxin-sensitive G proteins in stimulus-dependent human eosinophil degranulation. J Immunol 1991;147:3466-73.
26. Hansel TT, Pound JD, Pilling D, et al. Purification of human blood eosinophils by negative selection using immunomagnetic beads. J Immunol Methods 1989;122: 97-103.
27. Reimert CM, Venge P, Kharazmi A, Bendtzen K. Detection of eosinophil cationic protein (ECP) by an enzyme-linked immunosorbent assay. J Immunol Methods 1991;138:285-90.
28. 2+ dependent protein kinase. Biochem Biophys Res Commun 1986;135:397-402.
29. Kobayashi E, Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 1989;159:548-53.
30. Winqvist I. On the function of eosinophil granulocytes. With special reference to eosinophil cationic protein. Thesis, Medical Faculty, University of Lund, Sweden, 1984.
31. Newman SL, Mikus LK. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to C3. J Exp Med 1985;161:1414-31.
32. Neer EJ, Clapham DE. Roles of G prolein subunits in transmembrane signalling. Nature 1988;333:129-34.
33. Sengeløv H, Kjeldsen L, Borregaard N. Control of exocytosis in early neutrophil activation. J Immunol 1993;150:1535-43.
34. Henson PM, Henson JE, Fittschen C, Bratton DL, Riches DWH. Degranulation and secretion by phagocytic cells. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: basic principles and clinical correlates. New York: Raven Press, 1992:511-39.
35. Hamann KJ, Barker RL, Loegering DA, Gleich GJ. Comparative toxicity of purified human eosinophil granule proteins for newborn larvae of Trichinella spiralis. J Parasitol 1987;73:523-9.